2026-04-17T02:54:02Zhttps://recercat.cat/oai/request

oai:recercat.cat:11351/81202025-10-24T10:39:32Zcom_2072_378070com_2072_378040col_2072_378092

2025-10-24T10:39:32Z urn:hdl:11351/8120 All-cause mortality rates in adults with carbapenem-resistant Gram-negative bacterial infections: a comprehensive review of pathogen-focused, prospective, randomized, interventional clinical studies Lodise, Thomas P. Bassetti, Matteo Ferrer Roca, Ricard Naas, Thierry Niki, Yoshihito Paterson, David L. Zeitlinger, Markus Echols, Roger Malalties bacterianes gramnegatives - Mortalitat Medicaments antiinfecciosos Resistència als medicaments DISEASES::Bacterial Infections and Mycoses::Bacterial Infections::Gram-Negative Bacterial Infections Other subheadings::Other subheadings::Other subheadings::Other subheadings::/mortality CHEMICALS AND DRUGS::Organic Chemicals::Amides::Lactams::beta-Lactams::Carbapenems PHENOMENA AND PROCESSES::Microbiological Phenomena::Drug Resistance, Microbial ENFERMEDADES::infecciones bacterianas y micosis::infecciones bacterianas::infecciones por bacterias gramnegativas Otros calificadores::Otros calificadores::Otros calificadores::Otros calificadores::/mortalidad COMPUESTOS QUÍMICOS Y DROGAS::compuestos orgánicos::amidas::lactamas::beta-lactamas::carbapenems FENÓMENOS Y PROCESOS::fenómenos microbiológicos::farmacorresistencia microbiana Carbapenem resistance; Gram-negative; Cefiderocol Resistència als carbapenems; Gram-negatius; Cefiderocol Resistencia a carbapenémicos; Gram-negativo; Cefiderocol Introduction Pathogen-focused, randomized, controlled trials (PF-RCT) are important in the fight against carbapenem-resistant (CR) Gram-negative infections. Some recently approved antibiotics and older generic antibiotics with activity against CR Gram-negative bacteria were investigated in PF-RCTs in a variety of infections. Areas covered We searched Pubmed, Cochrane database and international clinical trial databases for PF-RCTs for the period between 2005 and 2020 and compared the study designs, patient populations, infection types, pathogens, and Day-28 all-cause mortality (ACM). Expert opinion PF-RCTs are particularly challenging to quantitatively assess and compare due to the heterogeneity in infection types, pathogens, CR mechanism, inclusion/exclusion criteria, and endpoints. Data interpretation is further complicated by lack of formal statistical analysis plans and/or non-inferiority design, and limited power across most PF-RCTs. The studies with new antibiotics (i.e. plazomicin, meropenem/vaborbactam, cefiderocol) ranked lower regarding feasibility, with relatively small sample sizes (analyzed: 37–118) versus the comparative effectiveness studies of older generic drugs (analyzed: 94–406). ACM ranged between 11.8% and 40% for CR Enterobacterales, 17.7% and 57.4% for CR Acinetobacter spp., and 20.0% and 30.8% for CR Pseudomonas aeruginosa. The information gathered must be considered carefully alongside the study limitations and caution should be exercised when making direct comparisons across trials. 2025-10-24T10:39:32Z 2025-10-24T10:39:32Z 2022-09-09T12:53:33Z 2022-09-09T12:53:33Z 2022-05 info:eu-repo/semantics/article info:eu-repo/semantics/publishedVersion http://hdl.handle.net/11351/8120 Expert Review of Anti-infective Therapy;20(5) https://doi.org/10.1080/14787210.2022.2020099 Attribution-NonCommercial-NoDerivatives 4.0 International http://creativecommons.org/licenses/by-nc-nd/4.0/ info:eu-repo/semantics/openAccess Taylor & Francis Scientia